Proteasome inhibitors: From in vitro uses to clinical trials

Journal of Peptide Science

Volumn 6, Issue 9, 2000, Pages 478-488

  Jennifer Rivett, A ^a   Gardner, Robert C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antigen presentation; Cancer; Cell cycle; Epoxomicin; Intracellular proteolysis; Lactacystin; Peptidyl boronic acid; Ubiquitin

Indexed keywords

3,4 DICHLOROISOCOUMARIN; ACLARUBICIN; ALDEHYDE DERIVATIVE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CARBOXYPEPTIDASE C; DIAZOMETHANE; EPOXOMICIN; GLIOTOXIN; GLYOXAL DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; PEPTIDE CHLOROMETHYL KETONE; PEPTIDE DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; SULFONE DERIVATIVE; UNCLASSIFIED DRUG; VINYL DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTHRITIS; ARTICLE; ASTHMA; BURKITT LYMPHOMA; CACHEXIA; CANCER; CATALYSIS; CELL CYCLE; CELL DIVISION; CELL FUNCTION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; IN VITRO STUDY; INFLAMMATION; LOEFFLER PNEUMONIA; MELANOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; AUTOIMMUNE DISEASES; CLINICAL TRIALS; CYSTEINE ENDOPEPTIDASES; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; HUMAN; INFLAMMATION; MOLECULAR STRUCTURE; MULTIENZYME COMPLEXES; PEPTIDE HYDROLASES; PROBABILITY; PROTEASE INHIBITORS; SUPPORT, NON-U.S. GOV'T;

ANIMALIA;

EID: 0033824673     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1387(200009)6:9<478::AID-PSC285>3.0.CO;2-F     Document Type: Article

References (91)

1. Structure and functions of the 20S and 26S proteasomes
2. The proteasome: Paradigm of a self-compartmentalizing protease
3. The ubiquitin-proteasome pathway: On protein death and cell life
4. Endoplasmic reticulum degradation: Reverse protein flow of no return
5. ER-associated and proteasome mediated protein degradation: How two topologically restricted events came together
6. Proteasomes and antigen processing
7. Degradation of cell proteins and the generation of MHC class I-presented peptides
8. The multicatalytic proteinase of mammalian cells
9. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation
10. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
11. Roles of ubiquitin-mediated proteolysis in cell cycle control
12. Ornithine Decarboxylase is degraded by the 26S-proteasome without ubiquitination
13. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4Å resolution
14. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation
15. The structures of HsIU and the ATP-dependent protease HsIU-HsIV
16. Proteasome from thermoplasma acidophilum: A threonine protease
17. Structure of 20S proteasome from yeast at 2.4Å resolution
18. The 20S proteasome: Subunits and functions
19. Identical subunit topographies of human and yeast 20S proteasomes
20. Processing of N3: A mammalian proteasome beta-type subunit
21. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly
22. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation
23. 20 S proteasomes are assembled via distinct precursor complexes. Processing of LMP2 and LMP7 proproteins takes place in 13-16 S preproteasome complexes
24. Biogenesis of eukaryotic 20S proteasomes: The complex maturation pathway of a complex enzyme
25. Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly
26. Cation-sensitive neutral endopeptidase: Isolation and specificity of the bovine pituitary enzyme
27. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
28. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: Development of a continuous assay and inhibition by tripeptide aldehydes and clasto-Lactacystin β-lactone
29. Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues
30. Peptidylglutamyl-peptide hydrolase activity of the multicatalytic proteinase complex: Evidence for a new high-affinity site, analysis of cooperative kinetics, and the effect of magnesium ions
31. The multicatalytic proteinase complex (proteasome): Structure and conformational changes associated with changes in proteolytic activity
32. A novel chymotrypsin-like component of the multicatalytic proteinase complex optimally active at acidic pH
33. Contribution of proteasomal β-subunits to the cleavage of peptide substrates analyzed with yeast mutants
34. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown
35. Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: A newly discovered mechanism for modulating the multicatalytic proteinase complex
36. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome
37. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes
38. Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity
39. 20S proteasome from LMP7 knock out mice reveals altered proteolytic activities and cleavage site preferences
40. Proteasome beta-type subunits: Unequal roles of propeptides in core particle maturation and a hierarchy of active site function
41. The multicatalytic and 26S proteases
42. The proteasome: A novel protease regulated by multiple mechanisms
43. The proteasome activator 11 S REG (PA28) and class I antigen presentation
44. Simultaneous binding of PA28 and PA700 activators to 20S proteasomes
45. Reaction of serine proteases with substituted isocoumarins: Discovery of 3,4-dichloroisocoumarin: A new general mechanism based serine protease inhibitor
46. Use of serine-protease inhibitors as probes for the different proteolytic activities of the rat liver multicatalytic proteinase complex
47. A 3,4-dichloroisocoumarin-resistant component of the multicatalytic proteinase complex
48. Multicatalytic endopeptidase complex: Proteasome
49. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes
50. Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: A novel catalytic activity in proteasome
51. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
52. A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell
53. Bivalency as a principle for proteasome inhibition
54. Potent α-ketocarbonyl and boronic ester derived inhibitors of proteasome
55. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
56. Characterization of peptidyl boronic acid inhibitors of mammalian 20S and 26S proteasomes and their inhibition of proteasomes in cultured cells
57. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals)
58. Reaction of proteasomes with peptidylchloromethanes and peptidyldiazomethanes
59. Covalent modification of the active site threonine of proteasomal β-subunits and the Escherichia coli homolog HsIV by a new class of inhibitors
60. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells
61. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
62. Lactacystin and clasto-Lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation
63. Mechanistic studies on the inactivation of the proteasome by lactacystin
64. Active site-directed inhibitors of Rhodococcus 20S proteasome
65. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity
66. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome
67. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome
68. Catalytic properties of 26S and 20S proteasomes and radiolabeling of MB1, LMP7, and C7 subunits associated with trypsin-like and chymotrypsin-like activities
69. Reaction of [14C]-3,4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complexes (proteasomes)
70. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes
71. Degradation of CFTR by the ubiquitin-proteasome pathway
72. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing
73. The protease inhibitor, N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum
74. P53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts
75. Alzheimer's disease: Correlation of the suppression of beta-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome
76. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme
77. A giant protease with potential to substitute for some functions of the proteasome
78. A proteolytic system that compensates for loss of proteasome function
79. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors
80. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells
81. The role of the ubiquitin-proteasome pathway in apoptosis
82. Dephosphorylation targets Bc1-2 for ubiquitin-dependent degradation: A link between the apoptosome and the proteasome pathway
83. Novel dipeptidyl proteasome inhibitors overcome Bc1-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
84. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
85. Epoxomicin: A new antitumor agent of microbial origin
86. Proteasome inhibition: A novel mechanism to combat asthma
87. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519(1)
88. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis
89. Proteasome inhibitors: A novel class of potent and effective antitumor agents
90. Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo
91. A new model of cancer cachexia: Contribution of the ubiquitin-proteasome pathway